Identification of novel candidate biomarkers of epithelial ovarian cancer by profiling the secretomes of three-dimensional genetic models of ovarian carcinogenesis

Senescent Fibroblasts Promote Neoplastic Transformation of Partially Transformed Ovarian Epithelial Cells in a Three-dimensional Model of Early Stage Ovarian Cancer

(2015) Kate Lawrenson et al.   NEOPLASIA

HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET)

(2013) Sofie L. Antonsen et al.   ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA

Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes

(2013) P-N Teng et al.   BRITISH JOURNAL OF CANCER

Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models

(2013) Ruth Perets et al.   CANCER CELL

Serum HE4 as a prognostic marker in endometrial cancer — A population based study

(2013) Donal J. Brennan et al.   GYNECOLOGIC ONCOLOGY

Emerging landscape of oncogenic signatures across human cancers

(2013) Giovanni Ciriello et al.   NATURE GENETICS

LGALS3BP, lectin galactoside-binding soluble 3 binding protein, promotes oncogenic cellular events impeded by antibody intervention

(2013) P Stampolidis et al.   ONCOGENE

Fatty Acid Synthase Is a Potential Therapeutic Target in Estrogen Receptor-/Progesterone Receptor-Positive Endometrioid Endometrial Cancer

(2013) Mohammed Tanjimur Rahman et al.   ONCOLOGY

LGALS3BP regulates centriole biogenesis and centrosome hypertrophy in cancer cells

(2013) Marie-Laure Fogeron et al.   Nature Communications

curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome

(2013) Benjamin Frederick Ganzfried et al.   Database-The Journal of Biological Databases and Curation

Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas

(2012) M T Rahman et al.   BRITISH JOURNAL OF CANCER

Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass

(2012) Mona Aarenstrup Karlsen et al.   GYNECOLOGIC ONCOLOGY

Clinicopathologic and Immunohistochemical Features of Ovarian Clear Cell Carcinomas in Comparison With Type I and Type II Tumors

(2012) Gian Franco Zannoni et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas

(2012) Michael S Anglesio et al.   JOURNAL OF PATHOLOGY

BRCAness Profile of Sporadic Ovarian Cancer Predicts Disease Recurrence

(2012) Weiya Z. Wysham et al.   PLoS One

High-grade serous ovarian cancer arises from fallopian tube in a mouse model

(2012) J. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

FKBP4 is regulated by HOXA10 during decidualization and in endometriosis

(2012) Huan Yang et al.   REPRODUCTION

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients

(2011) E Bignotti et al.   BRITISH JOURNAL OF CANCER

Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients

(2011) Fabio Morandi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Modelling genetic and clinical heterogeneity in epithelial ovarian cancers

(2011) Kate Lawrenson et al.   CARCINOGENESIS

Proteomic Approach Reveals FKBP4 and S100A9 as Potential Prediction Markers of Therapeutic Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer

(2011) Won Suk Yang et al.   JOURNAL OF PROTEOME RESEARCH

Quantitative profiling of serum samples using TMT protein labelling, fractionation and LC–MS/MS

(2011) John Sinclair et al.   METHODS

Blockade of Fatty Acid Synthase Induces Ubiquitination and Degradation of Phosphoinositide-3-Kinase Signaling Proteins in Ovarian Cancer

(2011) K. Tomek et al.   MOLECULAR CANCER RESEARCH

A targeted proteomics–based pipeline for verification of biomarkers in plasma

(2011) Jeffrey R Whiteaker et al.   NATURE BIOTECHNOLOGY

Increased tissue immunoexpression of YKL-40 protein in high grade serous ovarian cancers

(2011) Paweł Stawerski et al.   PATHOLOGY RESEARCH AND PRACTICE

Modeling high-grade serous ovarian carcinogenesis from the fallopian tube

(2011) A. M. Karst et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunohistochemical expression of epidermal growth factor receptor, E-cadherin, and matrix metalloproteinase–9 in ovarian epithelial cancer and relation to patient deaths

(2010) Hanan AlSaeid Alshenawy   Annals of Diagnostic Pathology

Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF-  Pathway Signaling Indicates Response to Primary Chemotherapy

(2010) M. S. Carey et al.   CLINICAL CANCER RESEARCH

Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase

(2010) Ann Smith Sehdev et al.   MODERN PATHOLOGY

A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24

(2010) Ellen L Goode et al.   NATURE GENETICS

Molecular Characterization of 103 Ovarian Serous and Mucinous Tumors

(2010) Ildikó Vereczkey et al.   PATHOLOGY & ONCOLOGY RESEARCH

Trophoblastic Neoplasms Express Fatty Acid Synthase, Which May Be a Therapeutic Target via Its Inhibitor C93

(2009) Stefanie M. Ueda et al.   AMERICAN JOURNAL OF PATHOLOGY

YKL-40 tissue expression and plasma levels in patients with ovarian cancer

(2009) Estrid VS Høgdall et al.   BMC CANCER

Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)

(2009) Usha Menon et al.   LANCET ONCOLOGY